C o r p o r a t e P r e s e n t a t i o n J u l y 2 0 2 0 - - PowerPoint PPT Presentation

magicmedindustries.com

1

C o r p o r a t e P r e s e n t a t i o n

J u l y 2 0 2 0

magicmedindustries.com

2

This presentation contains certain statements that may be deemed "forward-looking statements". All statements in this document, other than statements of historical fact, that address events or developments that MagicMed Industries (“the Company”) expects to occur, are forward looking

• statements. Forward looking statements are statements that are not historical facts and are generally,

but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward- looking statements. Factors that could cause the actual results to differ materially from those in forward looking statements include, failure to successfully negotiate or subsequently close such transactions, inability to obtain required shareholder

• r regulatory approvals, uncertainty with respect to findings under general economic, market or

business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward looking statements are based on the beliefs, estimates and

• pinions of the Company's management on the date the statements are made. The Company

undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change, other than as required under applicable securities laws.

Forward Looking Statements

magicmedindustries.com

3

MagicMed Industries intends to partner with pharmaceutical and

• ther companies to develop psychedelic-derived medicinal and

licit consumer goods products. MagicMed’s molecular derivatives library, the Psybrary™ is anticipated to be an essential building block from which industry can develop new patented products. The initial focus of the Psybrary™ is on psilocybin, and is expected to be opportunistically expanded to other psychedelics like MDMA, ketamine, ibogaine, mescaline, and ayahuasca.

About MagicMed

magicmedindustries.com

4

Investment Highlights

Experienced Leadership: Proven team has previously developed and partnered opiate and cannabinoid programs with significant corporate partners. Invested Team: Entire current management and science team well invested in the company. Leveraging Strength: Relationships with established pharmaceutical / consumer good manufacturers will be built upon. Opportunistic: Deep science and business expertise enables rapid Psybrary™ expansion to a broad range of psychedelic derivatives. Short Term Milestones: New derivatives, patents and first partner engagements all targeted for 2020. Solid Business Model: Controlled cost structure with sustainable near-term revenues via milestone-based compensation model. Bluesky: Royalty sharing opens the door to participating in potential long-term big pharma market revenues.

magicmedindustries.com

5

Improved Products Needed To Treat Psychological Indications

• Pharma is looking for more effective and safer products

to address numerous psychological indications that are growing in need and that are currently poorly treated.

• Psychedelic agents have recently shown promise in this

area but are limited in market potential because they require in-clinic administration and therapist oversight.

• In order to respond to increased needs and to create

broader market share, the pharma industry will require scientifically engineered versions of natural psychedelic molecules to improve on therapeutic benefit and to reduce toxicities (side effects).

• Once developed and approved, new medicinal products

will be useful for both prescribed and in-clinic administration to patients.

magicmedindustries.com

6

Why Pharma Needs MagicMed

• Creation of new psychedelic-based medicinal

products requires innovative processes, technology and expertise that pharma and consumer goods companies do not possess internally.

• Numerous companies are aspiring to develop new

psychedelic-derived pharmaceutical, nutraceutical, and consumer goods products.

• The MagicMed team has previously engaged with

large industrial partners to develop new derivatives in other medicinal product markets, such as opiates and cannabinoids.

• The MagicMed Psybrary™ and field expertise

provides the concrete head start necessary for success in a competitive environment.

magicmedindustries.com

7

• MagicMed scientists start with a natural psychedelic

molecule such as psilocybin and modify its structure to create many new derivative molecules which will form part of the MagicMed Psybrary™.

• The proprietary scientific tools MagicMed employs for

its derivatizations are trade secrets developed in-house from our decades of research and development in the field of natural product biochemistry.

• MagicMed partners will be able to search, select and test

from the derivatives in the Psybrary™ and use them as a building block for their own product development based

• n the indication that they are targeting (anxiety,

depression, addiction, PTSD and many others).

• The MagicMed team will then continue to work with its

partners to further define and improve upon their selected derivative molecules to create finished medicinal product candidates and, in future, licit consumer products.

MagicMed Process

magicmedindustries.com

8

Natural molecules such as psilocybin cannot be patented as a molecular composition. New molecular derivative compositions in the Psybrary™ are patentable as are MagicMed’s proprietary methods

• f manufacturing the derivatives within the Psybrary™.

MagicMed plans to file numerous patents to stake broad claims over the new derivative molecules contained in the Psybrary™. MagicMed’s partners will in turn potentially gain a significant edge over their competitors in new product development based on Psybrary™ molecules that are fully patent protected.

Building Intellectual Property Assets

magicmedindustries.com

9

Source: clinicaltrials.gov

Major Underserved Pharmaceutical Markets

• Pharmaceutical market opportunities for psychedelic

derivatives, especially Psilocybin, are estimated in the billions of dollars, with encouraging early clinical data being generated for many indications.

• Moreover, consumer goods market applications are

anticipated to follow in future as licit consumer markets

• pen up through decriminalization.
• It is expected that future pharma partners and other

consumer goods companies will actively seek improved psychedelic-derived molecules for product development.

• The MagicMed Psybrary™ is designed to provide

partners with a significant head start in the development of new medicinal and other products.

magicmedindustries.com

10

• The numerous and distinct medicinal markets allow us to work with

multiple major industry partners:

▪

Diversified partners allow for a conservative, multiple base hit strategy.

▪

Pharma partnerships will be the focus although we will add on consumer goods partnerships in future as decriminalization begins to open new licit consumer goods markets.

▪

Partners will pay fixed and variable costs plus milestone payments enabling MagicMed to quickly reach positive cash flow.

▪

Long-term product royalties offer the larger blue-sky

• pportunities.
• While we are working with partners and maintaining positive

revenues, we will continue to expand the Psybrary™, a sought-after industry asset that will grow in value over time.

Our Business Strategy

magicmedindustries.com

11

Objective Timelines

• Lab, science team expansion
• University partnership
• Psybrary™ development
• Multiple patent filings
• Target: Onboard 1st partner

2020

• Ongoing Psybrary™ expansion
• Expansion of patent filings
• Target: Additional partners
• Target: Public listing Q1/Q2
• Target: Q2 Cash flow positive

2021

• Increased partners
• Receipt of multiple milestone

payments

• Diversify to consumer goods

partners potentially

2022

magicmedindustries.com

12

For over 25 years the MagicMed team has been discovering building blocks and patenting new molecular derivatives in the fields of opiates, cannabinoids, and ephedra. Now the team has turned its extensive expertise to the psychedelics market.

Leadership

• Dr. Joseph Tucker is a seasoned executive

who has built several publicly traded biotechnology companies. He has worked closely with the MagicMed Science team since 2013. As CEO of MagicMed Industries,

• Dr. Tucker focuses on partnership

development, capital raising and the pursuit

• f a successful exit strategy.
• Dr. Joseph Tucker

CEO

• Dr. Jillian Hagel

COO

• Dr. Jillian Hagel has previously held

COO and Vice President roles in the biotechnology industry. She focuses

• n Science team coordination and

patent filings. Dr. Hagel will lead the Science team’s laser focus on delivering partner milestones.

• Dr. Peter Facchini has previously held the Chief

Scientific Officer role at other publicly-traded and private biotechnology companies. A recognized leader in the development of new molecular derivatives, Dr. Facchini has published more than 160 scientific papers and holds 20 patents in the

• field. At MagicMed Industries Dr. Facchini is

applying his focus to the creation and patenting

• f psychedelics-derivatives.
• Dr. Peter Facchini

CSO

magicmedindustries.com

13

Shares Outstanding: 13.7 million Warrants*: 13.7 million Options**: Fully Diluted: 27.4 million Total funds raised to date: $0.6 million

Corporate Structure

* 5 year warrants at $0.25 strike price held by management, scientists and strategic investors only. No further warrants to be issued until after a go-public transaction. ** Options to be issued to management and board only after a go-public transaction.

magicmedindustries.com

14

T h a n k Yo u

magicmedindustries.com

For more information please contact:

• Dr. Joseph Tucker, PhD

CEO jtucker@magicmedindustries.com